Although further studies are needed to evaluate the prognostic effect of HER2 status in CRCs, adding anti-HER2 inhibitor alone or combination therapy is a promising treatment option for better clinical outcomes in patients with advanced HER2 amplified CRC. This evidence concerns the gene ERBB2 and colorectal carcinoma.